SURGERY PARTNERS INC (SGRY) Stock Fundamental Analysis
USA - NASDAQ:SGRY - US86881A1007 - Common Stock
15.06 USD
-0.22 (-1.44%)
15.09 USD
+0.03 (+0.2%)
We assign a fundamental rating of 4 out of 10 to SGRY. SGRY was compared to 100 industry peers in the Health Care Providers & Services industry. While SGRY is still in line with the averages on profitability rating, there are concerns on its financial health. SGRY has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SGRY had positive earnings in the past year.
SGRY had a positive operating cash flow in the past year.
SGRY had negative earnings in each of the past 5 years.
Each year in the past 5 years SGRY had a positive operating cash flow.
1.2 Ratios
With a Return On Assets value of -2.27%, SGRY is not doing good in the industry: 61.00% of the companies in the same industry are doing better.
SGRY has a Return On Equity (-10.32%) which is comparable to the rest of the industry.
SGRY has a Return On Invested Capital of 5.18%. This is comparable to the rest of the industry: SGRY outperforms 58.00% of its industry peers.
SGRY had an Average Return On Invested Capital over the past 3 years of 5.03%. This is below the industry average of 9.40%.
The 3 year average ROIC (5.03%) for SGRY is below the current ROIC(5.18%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -10.32% | ||
| ROIC | 5.18% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
1.3 Margins
SGRY has a Operating Margin of 14.96%. This is amongst the best in the industry. SGRY outperforms 89.00% of its industry peers.
SGRY's Operating Margin has been stable in the last couple of years.
SGRY has a Gross Margin of 26.51%. This is comparable to the rest of the industry: SGRY outperforms 53.00% of its industry peers.
In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.51% |
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
2. Health
2.1 Basic Checks
SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for SGRY has been increased compared to 1 year ago.
The number of shares outstanding for SGRY has been increased compared to 5 years ago.
Compared to 1 year ago, SGRY has a worse debt to assets ratio.
2.2 Solvency
SGRY has an Altman-Z score of 0.74. This is a bad value and indicates that SGRY is not financially healthy and even has some risk of bankruptcy.
SGRY's Altman-Z score of 0.74 is on the low side compared to the rest of the industry. SGRY is outperformed by 74.00% of its industry peers.
The Debt to FCF ratio of SGRY is 20.39, which is on the high side as it means it would take SGRY, 20.39 years of fcf income to pay off all of its debts.
SGRY has a worse Debt to FCF ratio (20.39) than 60.00% of its industry peers.
SGRY has a Debt/Equity ratio of 1.98. This is a high value indicating a heavy dependency on external financing.
SGRY has a Debt to Equity ratio of 1.98. This is in the lower half of the industry: SGRY underperforms 74.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.98 | ||
| Debt/FCF | 20.39 | ||
| Altman-Z | 0.74 |
ROIC/WACC0.57
WACC9.06%
2.3 Liquidity
A Current Ratio of 1.93 indicates that SGRY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.93, SGRY is in the better half of the industry, outperforming 76.00% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that SGRY should not have too much problems paying its short term obligations.
With a decent Quick ratio value of 1.78, SGRY is doing good in the industry, outperforming 70.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
SGRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.02%.
SGRY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
The Revenue has been growing by 11.20% on average over the past years. This is quite good.
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
3.2 Future
The Earnings Per Share is expected to grow by 21.60% on average over the next years. This is a very strong growth
SGRY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.15% yearly.
EPS Next Y-6.74%
EPS Next 2Y6.36%
EPS Next 3Y10.25%
EPS Next 5Y21.6%
Revenue Next Year8.89%
Revenue Next 2Y9.24%
Revenue Next 3Y9.12%
Revenue Next 5Y10.15%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 19.31, which indicates a rather expensive current valuation of SGRY.
SGRY's Price/Earnings ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 67.00% of the companies in the same industry.
SGRY's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.56.
Based on the Price/Forward Earnings ratio of 14.16, the valuation of SGRY can be described as correct.
Based on the Price/Forward Earnings ratio, SGRY is valued a bit cheaper than 77.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.62. SGRY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.31 | ||
| Fwd PE | 14.16 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 78.00% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, SGRY is valued cheaply inside the industry as 82.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.01 | ||
| EV/EBITDA | 8.15 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.36%
EPS Next 3Y10.25%
5. Dividend
5.1 Amount
SGRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
15.06
-0.22 (-1.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners75.05%
Inst Owner Change5.6%
Ins Owners1.12%
Ins Owner Change-0.09%
Market Cap1.93B
Revenue(TTM)3.11B
Net Income(TTM)-180.40M
Analysts81.11
Price Target28.87 (91.7%)
Short Float %17.88%
Short Ratio7.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.1%
Min EPS beat(2)-24.34%
Max EPS beat(2)24.15%
EPS beat(4)2
Avg EPS beat(4)-2.82%
Min EPS beat(4)-26.04%
Max EPS beat(4)24.15%
EPS beat(8)6
Avg EPS beat(8)7.1%
EPS beat(12)9
Avg EPS beat(12)175.54%
EPS beat(16)11
Avg EPS beat(16)112.22%
Revenue beat(2)0
Avg Revenue beat(2)-1.48%
Min Revenue beat(2)-2.1%
Max Revenue beat(2)-0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)2.34%
Revenue beat(8)3
Avg Revenue beat(8)-0.58%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)6
Avg Revenue beat(16)-0.88%
PT rev (1m)0%
PT rev (3m)-0.81%
EPS NQ rev (1m)-1.92%
EPS NQ rev (3m)-10.98%
EPS NY rev (1m)-1.43%
EPS NY rev (3m)-2.37%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-0.54%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.31 | ||
| Fwd PE | 14.16 | ||
| P/S | 0.6 | ||
| P/FCF | 11.01 | ||
| P/OCF | 7.32 | ||
| P/B | 1.1 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.15 |
EPS(TTM)0.78
EY5.18%
EPS(NY)1.06
Fwd EY7.06%
FCF(TTM)1.37
FCFY9.08%
OCF(TTM)2.06
OCFY13.67%
SpS25.25
BVpS13.64
TBVpS-26.45
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.27% | ||
| ROE | -10.32% | ||
| ROCE | 6.56% | ||
| ROIC | 5.18% | ||
| ROICexc | 5.36% | ||
| ROICexgc | 19.21% | ||
| OM | 14.96% | ||
| PM (TTM) | N/A | ||
| GM | 26.51% | ||
| FCFM | 5.42% |
ROA(3y)-1.04%
ROA(5y)-1.46%
ROE(3y)-4.24%
ROE(5y)-9.69%
ROIC(3y)5.03%
ROIC(5y)4.49%
ROICexc(3y)5.23%
ROICexc(5y)4.72%
ROICexgc(3y)18.5%
ROICexgc(5y)17.9%
ROCE(3y)6.37%
ROCE(5y)5.69%
ROICexgc growth 3Y0.78%
ROICexgc growth 5Y0.88%
ROICexc growth 3Y4.99%
ROICexc growth 5Y3.37%
OM growth 3Y3.68%
OM growth 5Y1.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5Y-0.73%
F-Score4
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.98 | ||
| Debt/FCF | 20.39 | ||
| Debt/EBITDA | 5.37 | ||
| Cap/Depr | 55.13% | ||
| Cap/Sales | 2.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 40.92% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 0.74 |
F-Score4
WACC9.06%
ROIC/WACC0.57
Cap/Depr(3y)68.21%
Cap/Depr(5y)61.64%
Cap/Sales(3y)3.1%
Cap/Sales(5y)2.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y-6.74%
EPS Next 2Y6.36%
EPS Next 3Y10.25%
EPS Next 5Y21.6%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y11.86%
Revenue growth 5Y11.2%
Sales Q2Q%6.63%
Revenue Next Year8.89%
Revenue Next 2Y9.24%
Revenue Next 3Y9.12%
Revenue Next 5Y10.15%
EBIT growth 1Y8.03%
EBIT growth 3Y15.97%
EBIT growth 5Y12.77%
EBIT Next Year49.11%
EBIT Next 3Y22.59%
EBIT Next 5YN/A
FCF growth 1Y138.83%
FCF growth 3Y92.28%
FCF growth 5Y30.27%
OCF growth 1Y61.41%
OCF growth 3Y51.04%
OCF growth 5Y18.3%
SURGERY PARTNERS INC / SGRY FAQ
Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?
ChartMill assigns a fundamental rating of 4 / 10 to SGRY.
Can you provide the valuation status for SURGERY PARTNERS INC?
ChartMill assigns a valuation rating of 5 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.
How profitable is SURGERY PARTNERS INC (SGRY) stock?
SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for SGRY stock?
The Price/Earnings (PE) ratio for SURGERY PARTNERS INC (SGRY) is 19.31 and the Price/Book (PB) ratio is 1.1.
Is the dividend of SURGERY PARTNERS INC sustainable?
The dividend rating of SURGERY PARTNERS INC (SGRY) is 0 / 10 and the dividend payout ratio is 0%.